As the week comes to a close, many are looking forward to weekend plans. Whether it’s enjoying the outdoors, planning a holiday break, or connecting with loved ones, there are plenty of ways to unwind. However, recent events surrounding Eli Lilly’s weight loss treatment have raised questions about the FDA’s oversight of drug shortages. The FDA’s decision to end the shortage of Lilly’s tirzepatide has sparked controversy, with some pharmacies still reporting a lack of supplies. This has led to a legal battle between traditional retail pharmacies and compounding pharmacies.
In other news, AstraZeneca is facing potential job cuts in the UK due to government efforts to enforce profit-sharing measures related to nature’s genetic codes. The pharmaceutical industry is lobbying against these measures, citing concerns about a proposed global levy on drugs derived from digital sequence information (DSI). The use of DSI in drug development has become increasingly important, but there is growing frustration among biodiverse countries about how multinational companies are profiting from this information.
Overall, the pharmaceutical industry is facing challenges related to drug shortages and profit-sharing measures. It will be interesting to see how these issues unfold in the coming weeks and months. As always, stay safe and enjoy your weekend plans. Have a great time, and we’ll see you soon.
